News Releases Keyword Search Year None202420232022202120202019201820172016 Jan-02-2024 Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Dec-26-2023 Oncternal Therapeutics Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma Nov-09-2023 Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results Nov-02-2023 Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results Oct-26-2023 Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer Oct-25-2023 Oncternal Therapeutics Adds Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board Oct-05-2023 Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate Cancer Sep-07-2023 Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Board Aug-10-2023 Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results Aug-03-2023 Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »